IDH1 and glioma: In particular, the in-vivo longitudinal measurement of intratumoral 2HG levels could be critical to assess the pharmacodynamics of molecular drugs and ultimately the efficacy of targeted treatment, such as mutant-IDH1 inhibitors in glioma patients [52].